Note the date
$Acrivon Therapeutics(ACRV.US$ Acrivon Therapeutics: Acr-2316, a Potential First-in-Class Dual Wee1/Pkmyt1 Inhibitor, Ind Timeline Accelerated With Filing Now Expected in Q3 2024
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
